View Post

Nurse-Led Cognitive Behavioral Therapy Program Aids Management of Hot Flushes in Women With a History of Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Susan Moench, PhD, PA-C From: oncologynurseadvisor.com Patients with a history of breast cancer experiencing hot flushes and night sweats (HFNS) reported significant improvement in related quality-of-life measures following a nurse-led cognitive behavioral therapy (CBT) intervention compared with usual care, according to results of a randomized clinical trial published in Psycho-Oncology. Hot flushes and night sweats (HFNS) are commonly experienced …

View Post

Just a little physical activity pays big dividends to high risk breast cancer patients

In Clinical Studies News by Barbara Jacoby

By: SWOG From: medicalxpress.com Results of a comprehensive analysis of exercise and its protective role for high-risk breast cancer patients show that women who exercise not only live longer, but also are more likely to remain cancer-free after their treatment. What’s more, the study suggests that even a modest amount of exercise can be beneficial. “Aiming for as little as …

View Post

First Trial of Immunotherapy in Early-Stage Triple-Negative Breast Cancer Shows Promising Results

In Clinical Studies News by Barbara Jacoby

By: Danielle Ternyila From: targetedonc.com In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the findings from the interim analysis for the phase III KEYNOTE-522 study, which added pembrolizumab to neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer. The randomized, phase III KEYNOTE-522 clinical trial evaluated the benefit of adding the immune checkpoint inhibitor pembrolizumab (Keytruda) to …

View Post

Phase III trial evaluating Libtayo in NSCLC halted because of significant OS improvemen

In Clinical Studies News by Barbara Jacoby

From: cancerletter.com The primary endpoint of overall survival was met in a phase III trial comparing the PD-1 inhibitor Libtayo (cemiplimab) to platinum-doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer who tested positive for PD-L1 in ≥50% of tumor cells. Libtayo is jointly developed and commercialized by Regeneron and Sanofi under a global collaboration …

View Post

Optimal Sequencing Remains a Hurdle in Ovarian Cancer Treatment

In Clinical Studies News by Barbara Jacoby

By: Brittany Lovely From: onclive.com The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians. Bevacizumab (Avastin) continues to hold the most utility in this disease setting, but the addition of PARP inhibitors, and immunotherapy raises the question of how to best deliver efficient regimens to patients. …

View Post

FDA Approves Niraparib for Advanced Ovarian Cancer

In Clinical Studies News by Barbara Jacoby

By: Hannah Slater From: cancernetwork.com The FDA approved niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.1 Efficacy for the agent was investigated in the double-blind placebo-controlled phase III PRIMA trial, designed to evaluate niraparib, versus placebo, in …

View Post

Expert Highlights Benefit of PARP Inhibitors in BRCA+ Breast Cancer and Potentially Beyond

In Clinical Studies News by Barbara Jacoby

By: Ellie Leick From: onclive.com The use of PARP inhibitors has greatly expanded in the treatment of patients with BRCA-mutated breast cancer in recent years, according to Melinda L. Telli, MD, and research efforts are now examining these agents in novel combinations and beyond the BRCA setting. In January 2018, olaparib (Lynparza) joined the treatment arsenal for use as a …

View Post

Application of Neratinib in Breast Cancer Broadens

In Clinical Studies News by Barbara Jacoby

From: Rachel Narozniak, MA From: onclive.com The recent approval of neratinib (Nerlynx) in combination with capecitabine (Xeloda) for patients with late-stage, heavily pretreated HER2-positive breast cancer expanded the therapy’s established role in this disease setting. Neratinib was initially approved in July 2017 for the extended adjuvant treatment of adults with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab (Herceptin)-based therapy.1 …

View Post

European Commission Approves Takeda’s Alunbrig for First-Line ALK-positive Lung Cancer

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Japan-based pharmaceutical company Takeda today announced that the European Commission has approved its selective tyrosine kinase inhibitor brigatinib (Alunbrig) as a monotherapy for patients with ALK-positive, advanced non-small cell lung cancer as a first-line option. The approval presents another treatment option for patients with ALK rearrangements, who make up three-to-five percent of all patients with …

View Post

Caris Life Sciences Launches MI FOLFOXai, Improving Overall Survival by 50% for Metastatic Colorectal Cancer Patients

In Clinical Studies News by Barbara Jacoby

From: PR Newswire First AI-powered FOLFOX predictor to guide first-line metastatic colorectal cancer treatment Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the launch of MI FOLFOXai™, the newest addition to the company’s suite of comprehensive molecular science offerings. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of response …